Compositions and methods of use of multispecific antibodies

Abstract

Disclosed herein, in on aspect, is a method of treating an immune or inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to BCMA, CD19, or CD20 and CD3, thereby treating the immune or inflammatory disease.

Description

WSGR Docket No.: 69143-716.601COMPOSITIONS AND METHODS OF USE OF MULTISPECIFIC ANTIBODIESCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 749,293 filed January 24, 2025, which is incorporated herein by reference in its entirety.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 69143-716_601_SL.XML, created on January 14, 2026, which is 168,357 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety.INCORPORATION BY REFERENCE

[0003] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.SUMMARY

[0004] Disclosed herein, in one aspect, is a method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA) and cluster of differentiation (CD) 3, CD19 and CD3, or CD20 and CD3, thereby treating the autoimmune disorder.

[0005] In some aspects, the autoimmune disorder comprises an antibody-mediated rejection, an alloantibody-mediated disease or disorder, amyloidosis, anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, an anti -glomerular basement membrane disease (Goodpasture’s syndrome), anti-phospholipid antibody syndrome, anti -synthetase syndrome, autoimmune necrotizing myopathy, dilated cardiomyopathy, Graves’ disease, immunoglobulin (Ig) G4-related disease, immune vasculitis (IgA), immune thrombocytopenic purpura (ITP), microscopic polyangiitis, myasthenia gravis, necrotizing myopathy, neuromyelitis optica spectrum disorder (NMOSD), pemphigus vulgaris, thyroid eye disease (TED), tumor progression, allergy, atopic dermatitis, autoimmune hepatitis, behcet’s disease, bullous pemphigoid, celiac disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), guillain-barre syndrome, IgA nephropathy, inflammatory bowel disease, long COVID, lupus nephritis, membranous nephropathy, multiple sclerosis-primary progressive multiple sclerosis (MS-PPMS), multiple sclerosis-relapsing-remitting multiple sclerosis (MS-RRMS), myositis-dermatomyositis, myositis-inclusion body, myositis-polymyositis, polyneuropathy, organomegaly, endocrinopathy, M-protein, skinWSGR Docket No.: 69143-716.601changes (POEMS) syndrome, polyarteritis nodosa, postural orthostatic tachycardia syndrome (POTS), primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, raynaud’s syndrome, reactive arthritis, rheumatoid arthritis, scleroderma, sjogren’s syndrome, stiff person syndrome, systemic lupus, or type 1 diabetes.

[0006] Disclosed herein, in some aspect, is a method of eliminating, inhibiting, reducing, or depleting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen -binding fragment thereof that binds to BCMA and CD3, CD 19 and CD3, or CD20 and CD3, thereby eliminating, inhibiting, reducing, or depleting the immune cell.

[0007] In some aspects, the antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VH1), a first light chain variable region (VL1), a second heavy chain variable region (VH2), and a second light chain variable region (VL2). In some aspects, the antibody or antigen-binding fragment thereof comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain.

[0008] In some aspects, wherein: (a) the VH1 comprises complementarity determining region (CDR) 1, CDR2, and CDR3 comprising SEQ ID Nos: 66, 67, and 68, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 72, 73, and 74, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 69, 70, and 71, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 75, 76, and 77, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 78, 79, and 80, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 84, 85, and 86, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 81, 82, and 83, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 87, 88, and 89, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 90, 91, and 92, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 96, 97, and 98, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 93, 94, and 95, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 99, 100, and 101, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 102, 103, and 104, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 109, 110, and 111, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 105, 106, and 107, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 112, 113, and 114, respectively. In some aspects, VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 115, 116, and 117, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 118, 119, and 120, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 124, 125, and 126, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 121, 122, and 123, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 127, 128, and 129, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 130, 131, and 132, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprisingWSGR Docket No.: 69143-716.601SEQ ID Nos: 136, 137, and 138, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 133, 134, and 135, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 139, 140, and 141, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 142, 143, and 144, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 148, 149, and 150, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 145, 146, and 147, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 151, 152, and 153, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 154, 155, and 156, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 160, 161, and 162, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 157, 158, and 159, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 163, 164, and 165, respectively. In some aspects, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 166, 167, and 168, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 172, 173, and 174, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 169, 170, and 171, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 175, 176, and 177, respectively.

[0009] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1;WSGR Docket No.: 69143-716.601(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 7; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 4; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 4; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 7; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 10; or (d) the VL2WSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 9; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 13; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 10; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 14. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 9; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 13; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 10; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 14. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprisesWSGR Docket No.: 69143-716.601an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 11 ; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 15; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 12; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 16. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 11; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 15; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 12; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 16. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 17; (b) the VH2 comprises the amino acid sequence ofWSGR Docket No.: 69143-716.601SEQ ID NO: 21; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 18; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 17; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 21; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 18; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 22. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 20; or (d) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 19; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 23; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 20; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 19; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 23; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 20; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 24. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) theWSGR Docket No.: 69143-716.601VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 25; (b) the VL1 comprises the amino acid sequence of SEQ ID NO: 26; or (c) the VL2 comprises the amino acid sequence of SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 25; (b) the VL1 comprises the amino acid sequence of SEQ ID NO: 26; and (c) the VL2 comprises the amino acid sequence of SEQ ID NO: 108. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 27; or (b) the first light chain comprises the amino acid sequence of SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 27; and (b) the first light chain comprises the amino acid sequence of SEQ ID NO: 28. In some aspects, the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises anWSGR Docket No.: 69143-716.601amino acid sequence with at least 99% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises the amino acid sequence of SEQ ID NO: 29. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 30; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 34; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 31; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 30; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 34; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 31; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 35. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the firstWSGR Docket No.: 69143-716.601heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 32; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 36; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 33; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 32; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 36; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 33; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 37. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at leastWSGR Docket No.: 69143-716.60199% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 38; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 42; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 39; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 38; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 42; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 39; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 43.

[0010] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 45.

[0011] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 45.In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 40; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 44; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 41; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises the aminoWSGR Docket No.: 69143-716.601acid sequence of SEQ ID NO: 40; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 44; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 41; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 45. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 46; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 50; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 47; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 46; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 50; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 47; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 51. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 49; or (d) the secondWSGR Docket No.: 69143-716.601light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 48; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 52; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 49; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 48; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 52; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 49; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 53. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 95% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 54; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 56; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 55; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 54; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 56; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 55; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 58; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 62; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 59; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 58; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 62; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 59; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 63. In some aspects, wherein: (a) the firstWSGR Docket No.: 69143-716.601heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 61 ; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 60; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 64; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 61; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 60; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 64; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 61; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 65. In some aspects, the antibody or antigen-binding fragment thereof comprises teclistamab, elranatamab, linvoseltamab, alnuctamab, ABBV-383, HPN217, CM336, mosunetuzumab, glofitamab, epcoritamab, blincyto, odronextamab, imvotamab, R07507062, CN201, PIT565, MGD011, plamotamab, CMG1A46, IBP-B02, TQB2825, EX103, A319, AZD0486, JS203, YK102, CLN978, K193, JY108, or SCTB35. In some aspects, the antibody or antigen-binding fragment thereof is administered intramuscularly, subcutaneously, or intravenously. In some aspects, the antibody or antigen-binding fragment thereof is administered intravenously. In some aspects, the administering results in elimination or reduction of a B cell through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). In someWSGR Docket No.: 69143-716.601aspects, the administering results in elimination of a B cell expressing BCMA, CD 19, or CD20 through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). In some aspects, the administering results in a reduction in a B cell. In some aspects, the administering results in a reduction in an autoantibody. In some aspects, the immune or inflammatory disease is mediated by a B cell, a plasmablast, or a plasma cell. In some aspects, the immune or inflammatory disease is mediated by a mature B cell, a memory B cell, or an activated B cell. In some aspects, wherein the immune cell comprises an autoantibody, a B cell, a plasmablast, or a plasma cell. In some aspects, the immune cell comprises a mature B cell, a memory B cell, or an activated B cell.DETAILED DESCRIPTION

[0012] In the context of the present application, the following terms have the meanings ascribed to them unless specified otherwise:

[0013] As used throughout the specification and claims, the terms “a”, “an” and “the” are generally used in the sense that they mean “at least one”, “at least a first”, “one or more” or “a plurality” of the referenced components or steps, except in instances wherein an upper limit is thereafter specifically stated. For example, a “cleavage sequence”, as used herein, means “at least a first cleavage sequence” but includes a plurality of cleavage sequences. The operable limits and parameters of combinations, as with the amounts of any single agent, will be known to those of ordinary skill in the art in light of the present application.

[0014] The terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to generally refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non -amino acids. The terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

[0015] As used herein in the context of the structure of a polypeptide, “N -terminus” (or “amino terminus”) and “C -terminus” (or “carboxyl terminus”) generally refer to the extreme amino and carboxyl ends of the polypeptide, respectively.

[0016] The term “therapeutically effective amount,” as used herein, generally means the amount of a polypeptide variant or a polypeptide composition that, when administered to a patient for treating a disease or other undesirable medical condition, is sufficient to have a beneficial effect with respect to that disease or condition. The therapeutically effective amount will vary depending on the polypeptide variant or the polypeptide composition, the disease or condition and its severity, and the age, weight, etc. of the patient to be treated. Determining the therapeutically effective amount of a given polypeptide variant or a given polypeptide composition is generally within the ordinary skill of the art and requires no more than routine experimentation.

[0017] As used herein, the terms “about” and “approximately” are used interchangeably. Any numerals used herein with or without about / approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art. For example, the term “about” may refer to a range of values ±10%, ±5%, ±2%, or ±1% of a specified value. By way of an example, For example, the phrase “about 50%” may include from 45% to 55%, from 48% to 52%, or from 49% to 51%.WSGR Docket No.: 69143-716.601

[0018] As used herein, “heteromultimer” or “heteromultimeric protein” is a molecule comprising at least a first polypeptide and a second polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. In some embodiments, the heteromultimer has binding specificity for at least two different ligands or binding sites. The heteromultimer can comprise a “heterodimer” formed by the first and second polypeptide or can form higher order tertiary structures where polypeptides in addition to the first and second polypeptide are present.

[0019] The above definitions supersede any conflicting definition in any reference that is incorporated by reference herein. The fact that certain terms are defined, however, should not be considered as indicative that any term that is undefined is indefinite. Rather, all terms used are believed to describe the disclosure in terms such that one of ordinary skill can appreciate the scope and practice the present application. Antibody and Methods of Treatment

[0020] B cells play an important role in the pathogenesis of inflammatory diseases, immune diseases, and autoimmune diseases. Cluster of differentiation (CD) 20 is expressed on activated and memory B cells, the compartment responsible for certain autoimmune disease pathology. B-cell maturation antigen (BCMA) is a protein that regulates the survival, maturation, and proliferation of B-cells, and their differentiation into plasma cells. Cluster of differentiation (CD) 19 is a protein involved in B-cell development and activation, and is being studied as a potential target for immunotherapy in autoimmune diseases.

[0021] T cell engagers (TCEs) are a class of drugs that work by redirecting T cells to recognize and kill B cells expressing a target of interest, including BCMA, CD20, and CD 19. Disclosed herein is an antibody that binds to BCMA and CD3, CD20 and CD3, or CD19 and CD3.

[0022] Table 1 lists exemplary antibody amino acid sequences.Table 1. Exemplary Antibody Amino Acid Sequences.WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601WSGR Docket No.: 69143-716.601

[0023] In some embodiments, disclosed herein, is a method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen -binding fragment thereof that binds to B-cell maturation antigen (BCMA) and cluster of differentiation (CD) 3, thereby treating the autoimmune disorder. In some embodiments, disclosed herein, is a method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to cluster of differentiation (CD) 19 and CD3, thereby treating the autoimmune disorder. In some embodiments, disclosed herein, is a method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to cluster of differentiation (CD) 20 and CD3, thereby treating the autoimmune disorder. In some embodiments, disclosed herein, is a method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen -binding fragment thereof that binds to B-cell maturation antigen (BCMA) and cluster of differentiation (CD) 3, CD 19 and CD3, or CD20 and CD3, thereby treating the autoimmune disorder.

[0024] In some embodiments, the autoimmune disorder comprises an antibody -mediated rejection, an alloantibody-mediated disease or disorder, amyloidosis, anti-N-methyl-D-aspartate (NMDA) receptorWSGR Docket No.: 69143-716.601encephalitis, an anti -glomerular basement membrane disease (Goodpasture’s syndrome), anti-phospholipid antibody syndrome, anti -synthetase syndrome, autoimmune necrotizing myopathy, dilated cardiomyopathy, Graves’ disease, immunoglobulin (Ig) G4-related disease, immune vasculitis (IgA), immune thrombocytopenic purpura (ITP), microscopic polyangiitis, myasthenia gravis, necrotizing myopathy, neuromyelitis optica spectrum disorder (NMOSD), pemphigus vulgaris, thyroid eye disease (TED), tumor progression, allergy, atopic dermatitis, autoimmune hepatitis, behcet’s disease, bullous pemphigoid, celiac disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), guillain-barre syndrome, IgA nephropathy, inflammatory bowel disease, long COVID, lupus nephritis, membranous nephropathy, multiple sclerosis-primary progressive multiple sclerosis (MS-PPMS), multiple sclerosis-relapsing-remitting multiple sclerosis (MS-RRMS), myositis-dermatomyositis, myositis-inclusion body, myositis-polymyositis, polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome, polyarteritis nodosa, postural orthostatic tachycardia syndrome (POTS), primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, raynaud’s syndrome, reactive arthritis, rheumatoid arthritis, scleroderma, sjogren’s syndrome, stiff person syndrome, systemic lupus, or type 1 diabetes.

[0025] In some embodiments, the autoimmune disorder comprises an antibody-mediated rejection. In some embodiments, the autoimmune disorder comprises an alloantibody-mediated disease or disorder. In some embodiments, the autoimmune disorder comprises amyloidosis. In some embodiments, the autoimmune disorder comprises anti-N-methyl-D-aspartate (NMD A) receptor encephalitis. In some embodiments, the autoimmune disorder comprises an anti-glomerular basement membrane disease (Goodpasture’s syndrome). In some embodiments, the autoimmune disorder comprises anti-phospholipid antibody syndrome. In some embodiments, the autoimmune disorder comprises anti-synthetase syndrome. In some embodiments, the autoimmune disorder comprises autoimmune necrotizing myopathy. In some embodiments, the autoimmune disorder comprises dilated cardiomyopathy. In some embodiments, the autoimmune disorder comprises Graves’ disease. In some embodiments, the autoimmune disorder comprises immunoglobulin (Ig) G4-related disease. In some embodiments, the autoimmune disorder comprises immune vasculitis (IgA), immune thrombocytopenic purpura (ITP). In some embodiments, the autoimmune disorder comprises microscopic polyangiitis. In some embodiments, the autoimmune disorder comprises myasthenia gravis. In some embodiments, the autoimmune disorder comprises necrotizing myopathy. In some embodiments, the autoimmune disorder comprises neuromyelitis Optica spectrum disorder (NMOSD). In some embodiments, the autoimmune disorder comprises pemphigus vulgaris. In some embodiments, the autoimmune disorder comprises thyroid eye disease (TED). In some embodiments, the autoimmune disorder comprises tumor progression. In some embodiments, the autoimmune disorder comprises allergy. In some embodiments, the autoimmune disorder comprises atopic dermatitis. In some embodiments, the autoimmune disorder comprises autoimmune hepatitis. In some embodiments, the autoimmune disorder comprises Bechet’s disease. In some embodiments, the autoimmune disorder comprises bullous pemphigoid. In some embodiments, the autoimmune disorder comprises celiac disease. In some embodiments, the autoimmune disorder comprises chronic inflammatory demyelinatingWSGR Docket No.: 69143-716.601polyradiculoneuropathy (CIDP). In some embodiments, the autoimmune disorder comprises Guillain-Barre syndrome. In some embodiments, the autoimmune disorder comprises IgA nephropathy, inflammatory bowel disease. In some embodiments, the autoimmune disorder comprises long COVID. In some embodiments, the autoimmune disorder comprises lupus nephritis. In some embodiments, the autoimmune disorder comprises membranous nephropathy. In some embodiments, the autoimmune disorder comprises multiple sclerosis-primary progressive multiple sclerosis (MS-PPMS). In some embodiments, the autoimmune disorder comprises multiple sclerosis-relapsing-remitting multiple sclerosis (MS-RRMS). In some embodiments, the autoimmune disorder comprises myositis-dermatomyositis. In some embodiments, the autoimmune disorder comprises myositis-inclusion body. In some embodiments, the autoimmune disorder comprises myositis-polymyositis. In some embodiments, the autoimmune disorder comprises polyneuropathy. In some embodiments, the autoimmune disorder comprises organomegaly. In some embodiments, the autoimmune disorder comprises endocrinopathy. In some embodiments, the autoimmune disorder comprises M-protein. In some embodiments, the autoimmune disorder comprises skin changes (POEMS) syndrome. In some embodiments, the autoimmune disorder comprises polyarteritis nodosa. In some embodiments, the autoimmune disorder comprises postural orthostatic tachycardia syndrome (POTS. In some embodiments, the autoimmune disorder comprises primary biliary cirrhosis. In some embodiments, the autoimmune disorder comprises primary sclerosing cholangitis. In some embodiments, the autoimmune disorder comprises psoriasis. In some embodiments, the autoimmune disorder comprises psoriatic arthritis. In some embodiments, the autoimmune disorder comprises Raynaud’s syndrome. In some embodiments, the autoimmune disorder comprises reactive arthritis. In some embodiments, the autoimmune disorder comprises rheumatoid arthritis. In some embodiments, the autoimmune disorder comprises scleroderma. In some embodiments, the autoimmune disorder comprises Sjogren’s syndrome. In some embodiments, the autoimmune disorder comprises stiff person syndrome. In some embodiments, the autoimmune disorder comprises systemic lupus. In some embodiments, the autoimmune disorder comprises type 1 diabetes.In some embodiments, disclosed herein, is a method of eliminating, inhibiting, reducing, or depleting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to BCMA and CD3, CD19 and CD3, or CD20 and CD3, thereby eliminating, inhibiting, reducing, or depleting the immune cell. In some embodiments, disclosed herein, is a method of eliminating an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen -binding fragment thereof that binds to BCMA and CD3, thereby eliminating the immune cell. In some embodiments, disclosed herein, is a method of inhibiting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to BCMA and CD3, thereby inhibiting the immune cell. In some embodiments, disclosed herein, is a method of reducing an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen -binding fragment thereof that binds to BCMA and CD3, thereby reducing the immune cell. In some embodiments, disclosed herein, is a method of depleting an immuneWSGR Docket No.: 69143-716.601cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to BCMA and CD3, thereby depleting the immune cell. In some embodiments, disclosed herein, is a method of eliminating an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD 19 and CD3, thereby eliminating the immune cell. In some embodiments, disclosed herein, is a method of inhibiting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD 19 and CD3, thereby inhibiting the immune cell. In some embodiments, disclosed herein, is a method of reducing an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen -binding fragment thereof that binds to CD 19 and CD3, thereby reducing the immune cell. In some embodiments, disclosed herein, is a method of depleting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen -binding fragment thereof that binds to CD 19 and CD3, thereby depleting the immune cell. In some embodiments, disclosed herein, is a method of eliminating an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby eliminating the immune cell. In some embodiments, disclosed herein, is a method of inhibiting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby inhibiting the immune cell. In some embodiments, disclosed herein, is a method of reducing an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby reducing the immune cell. In some embodiments, disclosed herein, is a method of depleting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigenbinding fragment thereof that binds to CD20 and CD3, thereby depleting the immune cell.

[0026] In some embodiments, the antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VH1), a first light chain variable region (VL1), a second heavy chain variable region (VH2), and a second light chain variable region (VL2). In some embodiments, the antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VH1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a first light chain variable region (VL1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a second heavy chain variable region (VH2). In some embodiments, the antibody or antigen-binding fragment thereof comprises a second light chain variable region (VL2).

[0027] In some embodiments, the antibody or antigen-binding fragment thereof comprises a first heavy chain and a first light chain. In some embodiments, the antibody or antigen-binding fragment thereof comprises a second heavy chain, and a second light chain. In some embodiments, the antibody or antigenbinding fragment thereof comprises a first heavy chain, a first light chain, a second heavy chain, or a second light chain. In some embodiments, the antibody or antigen-binding fragment thereof comprises a first heavyWSGR Docket No.: 69143-716.601chain, a first light chain, a second heavy chain, and a second light chain. In some embodiments, wherein: (a) the VH1 comprises complementarity determining region (CDR) 1, CDR2, and CDR3 comprising SEQ ID Nos: 66, 67, and 68, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 72, 73, and 74, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 69, 70, and 71, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 75, 76, and 77, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 78, 79, and 80, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 84, 85, and 86, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 81, 82, and 83, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 87, 88, and 89, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 90, 91, and 92, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 96, 97, and 98, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 93, 94, and 95, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 99, 100, and 101, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 102, 103, and 104, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 109, 110, and 111, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 105, 106, and 107, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 112, 113, and 114, respectively. In some embodiments, the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 115, 116, and 117, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 118, 119, and 120, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 124, 125, and 126, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 121, 122, and 123, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 127, 128, and 129, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 130, 131, and 132, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 136, 137, and 138, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 133, 134, and 135, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 139, 140, and 141, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 142, 143, and 144, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 148, 149, and 150, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 145, 146, and 147, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 151, 152, and 153, respectively. In some embodiments, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 154, 155, and 156, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 160, 161, and 162, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 157, 158, and 159, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 163, 164, and 165, respectively. In some embodiments,WSGR Docket No.: 69143-716.601wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 166, 167, and 168, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 172, 173, and 174, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 169, 170, and 171, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 175, 176, and 177, respectively.

[0028] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 1, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage therebetween. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 5, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage therebetween. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 2, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage therebetween. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 6, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identityWSGR Docket No.: 69143-716.601to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at leastWSGR Docket No.: 69143-716.60191% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises the amino acidWSGR Docket No.: 69143-716.601sequence of SEQ ID NO: 1; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6. In some embodiments, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6.

[0029] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 3, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 7, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 4, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 8, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 7; (c)WSGR Docket No.: 69143-716.601the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 8. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 89% sequenceWSGR Docket No.: 69143-716.601identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprisesWSGR Docket No.: 69143-716.601an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 7; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 4; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 4; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 7; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8.

[0030] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 9, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 13, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 10, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 14, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence withWSGR Docket No.: 69143-716.601at least 75% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises anWSGR Docket No.: 69143-716.601amino acid sequence with at least 88% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ IDWSGR Docket No.: 69143-716.601NO: 9; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 9; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 13; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 10; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 9; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 13; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 10; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 14. In some embodiments, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 9; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 13; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 10; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 14.

[0031] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 11, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 15, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 12, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 16, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 70% sequence identity toWSGR Docket No.: 69143-716.601SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an aminoWSGR Docket No.: 69143-716.601acid sequence with at least 86% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 12; or (d) the secondWSGR Docket No.: 69143-716.601light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 11; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 15; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 12; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 11; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 15; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 12; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 16. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 11; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 15; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 12; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 16.In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 17, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 21, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,WSGR Docket No.: 69143-716.60186%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 18, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 22, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 22. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 22. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 22. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 22. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 22. In some embodiments, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises anWSGR Docket No.: 69143-716.601amino acid sequence with at least 84% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 18; or (d) the VL2WSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 17; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 21; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 18; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 17; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 21; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 18; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 22. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 17; (b)the VH2 comprises the amino acid sequence of SEQ ID NO: 21; (c)the VL1 comprises the amino acid sequence of SEQ ID NO: 18; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 22.

[0032] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 19, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100%WSGR Docket No.: 69143-716.601sequence identity to SEQ ID NO: 23, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 20, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 24, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 20; or (d) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 23; (c)the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 20; or (d) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at leastWSGR Docket No.: 69143-716.60183% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 20; or (d) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) theWSGR Docket No.: 69143-716.601first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 19; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 23; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 20; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO:WSGR Docket No.: 69143-716.60119; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 23; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 20; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 24. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 19; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 23; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 20; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 24.

[0033] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 25, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 26, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 108, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 25; (b) theWSGR Docket No.: 69143-716.601VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 108._In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 108._In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 108._In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 108._In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 108. _In some aspects, wherein: (a) theWSGR Docket No.: 69143-716.601VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 108. _In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 25; (b) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 26; or (c) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 25; (b) the VL1 comprises the amino acid sequence of SEQ ID NO: 26; or (c) the VL2 comprises the amino acid sequence of SEQ ID NO: 108. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 25; (b) the VL1 comprises the amino acid sequence of SEQ ID NO: 26; and (c) the VL2 comprises the amino acid sequence ofSEQ ID NO: 108.

[0034] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 27, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 28, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 28. InWSGR Docket No.: 69143-716.601some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chainWSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 27; or (b) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 27; or (b) the first light chain comprises the amino acid sequence of SEQ ID NO: 28. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 27; and (b) the first light chain comprises the amino acid sequence of SEQ ID NO: 28.

[0035] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 29, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some aspects, the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 29. In some aspects, the VH1 comprises an amino acid sequence with at least 99% sequenceWSGR Docket No.: 69143-716.601identity to SEQ ID NO: 29. In some aspects, the VH1 comprises the amino acid sequence of SEQ ID NO: 29.

[0036] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 30, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 34, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 31, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 35, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0037] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 82%WSGR Docket No.: 69143-716.601sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 91% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 30; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 34; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 31; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 30; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 34; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 31; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 35. In some aspects, wherein: (a) the VH1 comprisesWSGR Docket No.: 69143-716.601the amino acid sequence of SEQ ID NO: 30; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 34; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 31; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 35.

[0038] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 32, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 36, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 33, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 37, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0039] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 37. InWSGR Docket No.: 69143-716.601some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 90% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 37.

[0040] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 98% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 32; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 36; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 33; or (d) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 32; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 36; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 33; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 37. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 32; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 36; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 33; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 37.

[0041] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 38, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 42, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 39, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 43, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0042] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 75% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 42; (c) the VL1WSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ IDWSGR Docket No.: 69143-716.601NO: 42; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 38; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 42; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 39; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 38; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 42; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 39; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 43. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 38; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 42; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 39; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 43.

[0043] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 40, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 44, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 41, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 45, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0044] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 45. In some aspects,WSGR Docket No.: 69143-716.601wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 44; (c) the first light chain comprise s an amino acid sequence with at least 81 % sequence identity to SEQ ID NO : 41 ; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprisesWSGR Docket No.: 69143-716.601an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO:WSGR Docket No.: 69143-716.60140; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 40; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 44; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 41; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 40; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 44; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 41; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 45. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 40; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 44; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 41; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 45.

[0045] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 46, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 50, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 1 47, e.g., about 70%,WSGR Docket No.: 69143-716.60171%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 51, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0046] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ IDWSGR Docket No.: 69143-716.601NO: 50; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 94%WSGR Docket No.: 69143-716.601sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 46; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 50; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 47; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 46; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 50; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 47; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 51. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 46; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 50; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 47; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 51.

[0047] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 48, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 52, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, theWSGR Docket No.: 69143-716.601first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 49, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 53, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0048] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 48; (b) the second heavy chainWSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity toWSGR Docket No.: 69143-716.601SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 48; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 52; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 49; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 48; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 52; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 49; or (d) the second light chain comprises theWSGR Docket No.: 69143-716.601amino acid sequence of SEQ ID NO: 53. In some aspects, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 48; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 52; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 49; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 53.

[0049] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 54, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 56, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 55, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 57, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0050] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 82%WSGR Docket No.: 69143-716.601sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 91% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 54; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 56; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 55; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 54; (b) the VH2 comprises the amino acid sequence ofWSGR Docket No.: 69143-716.601SEQ ID NO: 56; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 55; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 57. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 54; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 56; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 55; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 57.

[0051] In some embodiments, the VH1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 58, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VH2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 62, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL1 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 59, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the VL2 comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 63, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0052] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 82%WSGR Docket No.: 69143-716.601sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acidWSGR Docket No.: 69143-716.601sequence with at least 91% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 63.

[0053] In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 58; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 62; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 59; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 63. In some aspects,WSGR Docket No.: 69143-716.601wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 58; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 62; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 59; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 63. In some aspects, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 58; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 62; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 59; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 63.

[0054] In some embodiments, the first heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 60, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second heavy chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 64, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the first light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 61, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between. In some embodiments, the second light chain comprises an amino acid sequence with about 70% to about 100% sequence identity to SEQ ID NO: 65, e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity, or any percentage there between.

[0055] In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 75% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises anWSGR Docket No.: 69143-716.601amino acid sequence with at least 81% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 81% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 82% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 83% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 84% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 86% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 87% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 88% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 89% sequence identity toWSGR Docket No.: 69143-716.601SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 89% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 91% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 92% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 93% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 94% sequence identity to SEQ ID NO: 65. In some embodiments, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 96% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequenceWSGR Docket No.: 69143-716.601with at least 97% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 97% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 98% sequence identity to SEQ ID NO: 65. In some aspects, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 60; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 64; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 61; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 65. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 60; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 64; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 61; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 60; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 64; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 61; and (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 65.

[0056] In some embodiments, the antibody or antigen-binding fragment thereof comprises teclistamab, elranatamab, linvoseltamab, alnuctamab, ABBV-383, HPN217, CM336, mosunetuzumab, glofitamab, epcoritamab, blincyto, odronextamab, imvotamab, R07507062, CN201, PIT565, MGD011, plamotamab, CMG1A46, IBP-B02, TQB2825, EX103, A319, AZD0486, JS203, YK102, CLN978, K193, JY108, or SCTB35. In some embodiments, the antibody or antigen-binding fragment thereof comprises teclistamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises elranatamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises linvoseltamab. In some embodiments, the antibody or antigen -binding fragment thereof comprises alnuctamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises ABBV-383. In some embodiments, the antibody or antigen-binding fragment thereof comprises HPN217. In some embodiments, the antibody or antigen-binding fragment thereof comprises CM336. In some embodiments, the antibody or antigen-binding fragment thereof comprises mosunetuzumab. In some embodiments, the antibody or antigen -binding fragment thereof comprises glofitamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises epcoritamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises blincyto. In some embodiments, the antibody or antigenbinding fragment thereof comprises odronextamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises imvotamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises R07507062. In some embodiments, the antibody or antigen-binding fragment thereof comprises CN201. In some embodiments, the antibody or antigen-binding fragment thereof comprises PIT565. In some embodiments, the antibody or antigen-binding fragment thereof comprises MGD011. InWSGR Docket No.: 69143-716.601some embodiments, the antibody or antigen-binding fragment thereof comprises plamotamab. In some embodiments, the antibody or antigen-binding fragment thereof comprises CMG1A46. In some embodiments, the antibody or antigen-binding fragment thereof comprises IBP-B02. In some embodiments, the antibody or antigen-binding fragment thereof comprises TQB2825. In some embodiments, the antibody or antigen -binding fragment thereof comprises EX 103. In some embodiments, the antibody or antigen-binding fragment thereof comprises A319. In some embodiments, the antibody or antigen-binding fragment thereof comprises AZD0486. In some embodiments, the antibody or antigenbinding fragment thereof comprises JS203 In some embodiments, the antibody or antigen-binding fragment thereof comprises YK102. In some embodiments, the antibody or antigen-binding fragment thereof comprises CLN978. In some embodiments, the antibody or antigen-binding fragment thereof comprises K193. In some embodiments, the antibody or antigen-binding fragment thereof comprises JY108. In some embodiments, the antibody or antigen-binding fragment thereof comprises SCTB35.

[0057] In some embodiments, the antibody or antigen-binding fragment thereof is administered intramuscularly, subcutaneously, or intravenously. In some embodiments, the antibody or antigen-binding fragment thereof is administered intramuscularly. In some embodiments, the antibody or antigen-binding fragment thereof is administered intravenously. In some embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously. In some embodiments, the administering results in elimination or reduction of a B cell through antibody -dependent cellular cytotoxicity (ADCC). In some embodiments, the administering results in elimination or reduction of a B cell through complementdependent cytotoxicity (CDC). In some embodiments, the administering results in elimination of a B cell expressing BCMA, CD 19, or CD20 through complement-dependent cytotoxicity (CDC). In some embodiments, the administering results in elimination of a B cell expressing CD 19 through complementdependent cytotoxicity (CDC). In some embodiments, the administering results in elimination of a B cell expressing CD20 through complement-dependent cytotoxicity (CDC). In some embodiments, the administering results in elimination of a B cell expressing BCMA through complement-dependent cytotoxicity (CDC). In some embodiments, the administering results in elimination of a B cell expressing BCMA, CD 19, or CD20 through antibody -dependent cellular cytotoxicity (ADCC). In some embodiments, the administering results in elimination of a B cell expressing BCMA through antibody -dependent cellular cytotoxicity (ADCC). In some embodiments, the administering results in elimination of a B cell expressing CD20 through antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the administering results in elimination of a B cell expressing CD 19 through antibody -dependent cellular cytotoxicity (ADCC). In some embodiments, the administering results in a reduction in a B cell. In some embodiments, the administering results in a reduction in an autoantibody. In some embodiments, the immune or inflammatory disease is mediated by a B cell, a plasmablast, or a plasma cell. In some embodiments, the immune or inflammatory disease is mediated by a B cell. In some embodiments, the immune or inflammatory disease is mediated by a plasmablast. In some embodiments, the immune or inflammatory disease is mediated by a plasma cell.WSGR Docket No.: 69143-716.601

[0058] In some embodiments, the immune or inflammatory disease is mediated by a mature B cell, a memory B cell, or an activated B cell. In some embodiments, the immune or inflammatory disease is mediated by a mature B cell. In some embodiments, the immune or inflammatory disease is mediated by a memory B cell. In some embodiments, the immune or inflammatory disease is mediated by an activated B cell. In some embodiments, wherein the immune cell comprises an autoantibody, a B cell, a plasmablast, or a plasma cell. In some embodiments, wherein the immune cell comprises an autoantibody. In some embodiments, wherein the immune cell comprises a B cell. In some embodiments, wherein the immune cell comprises a plasmablast. In some embodiments, wherein the immune cell comprises a plasma cell. In some embodiments, wherein the immune cell comprises a mature B cell, a memory B cell, or an activated B cell. In some embodiments, the immune cell comprises a mature B cell. In some aspects, the immune cell comprises a memory B cell. In some embodiments, the immune cell comprises an activated B cell.

[0059] The disclosure herein is further defined by the following list of numbered embodiments. 1. A method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA) and cluster of differentiation (CD) 3, CD 19 and CD3, or CD20 and CD3, thereby treating the autoimmune disorder. 2. The method of embodiment 1, wherein the autoimmune disorder comprises an antibody-mediated rejection, an alloantibody-mediated disease or disorder, amyloidosis, anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, an anti-glomerular basement membrane disease (Goodpasture’s syndrome), anti-phospholipid antibody syndrome, anti-synthetase syndrome, autoimmune necrotizing myopathy, dilated cardiomyopathy, Graves’ disease, immunoglobulin (Ig) G4-related disease, immune vasculitis (IgA), immune thrombocytopenic purpura (ITP), microscopic polyangiitis, myasthenia gravis, necrotizing myopathy, neuromyelitis optica spectrum disorder (NMOSD), pemphigus vulgaris, thyroid eye disease (TED), tumor progression, allergy, atopic dermatitis, autoimmune hepatitis, behcet’s disease, bullous pemphigoid, celiac disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), guillain-barre syndrome, IgA nephropathy, inflammatory bowel disease, long COVID, lupus nephritis, membranous nephropathy, multiple sclerosis-primary progressive multiple sclerosis (MS-PPMS), multiple sclerosis-relapsing-remitting multiple sclerosis (MS-RRMS), myositis-dermatomyositis, myositisinclusion body, myositis-polymyositis, polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome, polyarteritis nodosa, postural orthostatic tachycardia syndrome (POTS), primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, raynaud’s syndrome, reactive arthritis, rheumatoid arthritis, scleroderma, sjogren’s syndrome, stiff person syndrome, systemic lupus, or type 1 diabetes. 3. A method of eliminating, inhibiting, reducing, or depleting an immune cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to BCMA and CD3, CD19 and CD3, or CD20 and CD3, thereby eliminating, inhibiting, reducing, or depleting the immune cell. 4. The method of any one of embodiments 1 to 3, wherein the antibody or antigen-binding fragment thereof comprises a first heavy chain variable region (VH1), a first light chain variable region (VL1), a second heavy chain variable region (VH2), and a second light chain variable region (VL2). 5. The method of any one of embodiments 1 to 4,WSGR Docket No.: 69143-716.601wherein the antibody or antigen-binding fragment thereof comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain. 6. The method of any one of embodiments 1 to 5, wherein: (a) the VH1 comprises complementarity determining region (CDR) 1, CDR2, and CDR3 comprising SEQ ID Nos: 66, 67, and 68, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 72, 73, and 74, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 69, 70, and 71, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 75, 76, and 77, respectively. 7. The method of any one of embodiments 1 to 6, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 78, 79, and 80, respectively;(b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 84, 85, and 86, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 81, 82, and 83, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 87, 88, and 89, respectively. 8. The method of any one of embodiments 1 to 7, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 90, 91, and 92, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 96, 97, and 98, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 93, 94, and 95, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 99, 100, and 101, respectively. 9. The method of any one of embodiments 1 to 8, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 102, 103, and 104, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 109, 110, and 111, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 105, 106, and 107, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 112, 113, and 114, respectively. 10. The method of any one of embodiments 1 to 9, wherein the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 115, 116, and 117, respectively. 11. The method of any one of embodiments 1 to 10, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 118, 119, and 120, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 124, 125, and 126, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 121, 122, and 123, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 127, 128, and 129, respectively. 12. The method of any one of embodiments 1 to 11, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 130, 131, and 132, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 136, 137, and 138, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 133, 134, and 135, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 139, 140, and 141, respectively. 13. The method of any one of embodiments 1 to 12, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 142, 143, and 144, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 148, 149, and 150, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 145, 146, and 147, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 151, 152, and 153, respectively. 14. The method of any one of embodiments 1 to 13, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 154, 155, and 156, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprisingWSGR Docket No.: 69143-716.601SEQ ID Nos: 160, 161, and 162, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 157, 158, and 159, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 163, 164, and 165, respectively. 15. The method of any one of embodiments 1 to 14, wherein: (a) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 166, 167, and 168, respectively; (b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 172, 173, and 174, respectively; (c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 169, 170, and 171, respectively; and (d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 175, 176, and 177, respectively. 16. The method of any one of embodiments 1 to 15, wherein: (a) the VH1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 6. 17. The method of any one of embodiments 1 to 16, wherein: (a) the VH1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 6. 18. The method of any one of embodiments 1 to 17, wherein: (a) the VH1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 6. 19. The method of any one of embodiments 1 to 18, wherein: (a) the VH1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6. 20. The method of any one of embodiments 1 to 19, wherein: (a) the VH1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 1; (b) the VH2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 5; (c) the VL1 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 2; or (d) the VL2 comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 6. 21. The method of any one of embodiments 1 to 20, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; or (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6. 22. The method of any one of embodiments 1 to 21, wherein: (a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1; (b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5; (c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; and (d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6. 23. The method of any one of embodiments 1 to 22, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 3; (b) the second heavy chainWSGR Docket No.: 69143-716.601comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 8. 24. The method of any one of embodiments 1 to 23, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 8. 25. The method of any one of embodiments 1 to 24, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 8. 26. The method of any one of embodiments 1 to 25, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 8. 27. The method of any one of embodiments 1 to 26, wherein: (a) the first heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 3; (b) the second heavy chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 7; (c) the first light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 4; or (d) the second light chain comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 8. 28. The method of any one of embodiments 1 to 27, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 7; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 4; or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8. 29. The method of any one of embodiments 1 to 28, wherein: (a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 4; (c) the first light chain comprises the...

Claims

WSGR Docket No.: 69143-716.601CLAIMS WHAT IS CLAIMED IS:

1. A method of treating an autoimmune disorder in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA) and cluster of differentiation (CD) 3, CD 19 and CD3, or CD20 and CD3, thereby treating the autoimmune disorder.

2. The method of claim 1, wherein the autoimmune disorder comprises an antibody -mediated rejection, an alloantibody-mediated disease or disorder, amyloidosis, anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, an anti -glomerular basement membrane disease (Goodpasture’s syndrome), anti-phospholipid antibody syndrome, anti-synthetase syndrome, autoimmune necrotizing myopathy, dilated cardiomyopathy, Graves’ disease, immunoglobulin (Ig) G4-related disease, immune vasculitis (IgA), immune thrombocytopenic purpura (ITP), microscopic polyangiitis, myasthenia gravis, necrotizing myopathy, neuromyelitis optica spectrum disorder (NMOSD), pemphigus vulgaris, thyroid eye disease (TED), tumor progression, allergy, atopic dermatitis, autoimmune hepatitis, behcet’s disease, bullous pemphigoid, celiac disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), guillain-barre syndrome, IgA nephropathy, inflammatory bowel disease, long CO VID, lupus nephritis, membranous nephropathy, multiple sclerosis-primary progressive multiple sclerosis (MS-PPMS), multiple sclerosis-relapsing-remitting multiple sclerosis (MS-RRMS), myositis-dermatomyositis, myositis-inclusion body, myositis-polymyositis, polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome, polyarteritis nodosa, postural orthostatic tachycardia syndrome (POTS), primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, raynaud’s syndrome, reactive arthritis, rheumatoid arthritis, scleroderma, sjogren’s syndrome, stiff person syndrome, systemic lupus, or type 1 diabetes.

3. The method of claim 1, wherein the method comprises eliminating, inhibiting, reducing, or depleting an immune cell in a subject.

4. The method of claim 1, wherein the antibody or antigen -binding fragment thereof comprises a first heavy chain variable region (VH1), a first light chain variable region (VL1), a second heavy chain variable region (VH2), and a second light chain variable region (VL2).

5. The method of claim 1, wherein the antibody or antigen -binding fragment thereof comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain.

6. The method of claim 1, wherein:(a) the VH1 comprises complementarity determining region (CDR) 1, CDR2, and CDR3 comprising SEQ ID Nos: 66, 67, and 68, respectively;(b) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 72, 73, and 74, respectively;WSGR Docket No.: 69143-716.601(c) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 69, 70, and 71, respectively; and(d) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 75, 76, and 77, respectively; or(e) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 78, 79, and 80, respectively;(f) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 84, 85, and 86, respectively;(g) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 81, 82, and 83, respectively; and(h) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 87, 88, and 89, respectively; or(i) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 90, 91, and 92, respectively;(j) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 96, 97, and 98, respectively;(k) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 93, 94, and 95, respectively; and(l) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 99, 100, and 101, respectively; or(m)the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 102, 103, and 104, respectively;(n) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 109, 110, and 111, respectively;(o) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 105, 106, and 107, respectively; and(p) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 112, 113, and 114, respectively; or(q) wherein the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 115, 116, and 117, respectively; or(r) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 118, 119, and 120, respectively;WSGR Docket No.: 69143-716.601(s) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 124, 125, and 126, respectively;(t) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 121, 122, and 123, respectively; and(u) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 127, 128, and 129, respectively; or(v) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 130, 131, and 132, respectively;(w) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 136, 137, and 138, respectively;(x) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 133, 134, and 135, respectively; and(y) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 139, 140, and 141, respectively or(z) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 142, 143, and 144, respectively;(aa)the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 148, 149, and 150, respectively;(bb) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 145, 146, and 147, respectively; and(cc)the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 151,152, and 153, respectively or(dd) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 154, 155, and 156, respectively;(ee)the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 160,161, and 162, respectively;(ff) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 157, 158, and 159, respectively; and(gg) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 163, 164, and 165, respectively or(hh) the VH1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 166, 167, and 168, respectively;WSGR Docket No.: 69143-716.601(ii) the VH2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 172, 173, and 174, respectively;(jj) the VL1 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 169, 170, and 171, respectively; and(kk) the VL2 comprises CDR1, CDR2, and CDR3 comprising SEQ ID Nos: 175, 176, and 177, respectively.

7. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 1;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 5;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 2; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6.

8. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 1;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 5;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 2; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 6.

9. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 3;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 7;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 4; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 8.

10. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 3;(b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 7;WSGR Docket No.: 69143-716.601(c) the first light chain comprises the amino acid sequence of SEQ ID NO: 4; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 8.

11. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 9;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 13;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 10; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 14.

12. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 9;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 13;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 10; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 14.

13. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 11;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 15;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 12; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 16.

14. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 11; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 15; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 12; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 16.

15. The method of claim 1, wherein:WSGR Docket No.: 69143-716.601(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 17;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 21;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 18; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 22.

16. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 17;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 21;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 18; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 22.

17. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 19;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 23;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 20; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 24.

18. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 19; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 23; (c) the first light chain comprises the amino acid sequence of SEQ ID NO: 20; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 24.

19. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 25;- Ill -WSGR Docket No.: 69143-716.601(b) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 26; or(c) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 108.

20. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 25;(b) the VL1 comprises the amino acid sequence of SEQ ID NO: 26; and / or(c) the VL2 comprises the amino acid sequence of SEQ ID NO: 108.

21. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 27; or(b) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 28.

22. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 27; and / or (b) the first light chain comprises the amino acid sequence of SEQ ID NO: 28.

23. The method of claim 1, wherein the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 29.

24. The method of claim 1, wherein the VH1 comprises the amino acid sequence of SEQ ID NO: 29.

25. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 30;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 34;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 31; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 35.

26. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 30;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 34;WSGR Docket No.: 69143-716.601(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 31; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 35.

27. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 32;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 36;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 33; or(d) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 37.

28. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 32; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 36;(c) the first light chain comprises the amino acid sequence of SEQ ID NO: 33; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 37.

29. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 38;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 42;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 39; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 43.

30. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 38;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 42;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 39; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 43.

31. The method of claim 1, wherein:WSGR Docket No.: 69143-716.601(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 40;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 44;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 41; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 45.

32. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 40; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 44;(c) the first light chain comprises the amino acid sequence of SEQ ID NO: 41; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 45.

33. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 46;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 50;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 47; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 51.

34. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 46;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 50;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 47; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 51.

35. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 48;WSGR Docket No.: 69143-716.601(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 52;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 49; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 53.

36. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 48; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 52;(c) the first light chain comprises the amino acid sequence of SEQ ID NO: 49; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 53.

37. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 54;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 56;(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 55; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 57.

38. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 54;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 56;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 55; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 57.

39. The method of claim 1, wherein:(a) the VH1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 58;(b) the VH2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 62;WSGR Docket No.: 69143-716.601(c) the VL1 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 59; or(d) the VL2 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 63.

40. The method of claim 1, wherein:(a) the VH1 comprises the amino acid sequence of SEQ ID NO: 58;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 62;(c) the VL1 comprises the amino acid sequence of SEQ ID NO: 59; and / or(d) the VL2 comprises the amino acid sequence of SEQ ID NO: 63.

41. The method of claim 1, wherein:(a) the first heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 60;(b) the second heavy chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 64;(c) the first light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 61; or(d) the second light chain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 65.

42. The method of claim 1, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 60; (b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 64;(c) the first light chain comprises the amino acid sequence of SEQ ID NO: 61; and / or (d) the second light chain comprises the amino acid sequence of SEQ ID NO: 65.

43. The method of claim 1, wherein the antibody or antigen -binding fragment thereof comprises teclistamab, elranatamab, linvoseltamab, alnuctamab, ABBV-383, HPN217, CM336, mosunetuzumab, glofitamab, epcoritamab, blincyto, odronextamab, imvotamab, R07507062, CN201, PIT565, MGD0II, plamotamab, CMG1A46, IBP-B02, TQB2825, EX103, A319, AZD0486, JS203, YK102, CLN978, K193, JY108, or SCTB35.

44. The method of claim 1, wherein the antibody or antigen -binding fragment thereof is administered intramuscularly, subcutaneously, or intravenously.

45. The method of claim 1, wherein the administering results in elimination or reduction of a B cell through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).WSGR Docket No.: 69143-716.60146. The method of claim 1, wherein the administering results in a reduction in a B cell or an autoantibody.

47. The method of claim 1, wherein the immune or inflammatory disease is mediated by a B cell, a plasmablast, or a plasma cell.

48. The method of claim 1, wherein the immune or inflammatory disease is mediated by a mature B cell, a memory B cell, or an activated B cell.

49. The method of claim 1, wherein the immune cell comprises an autoantibody, a B cell, a plasmablast, or a plasma cell.

50. The method of claim 1, wherein the immune cell comprises a mature B cell, a memory B cell, or an activated B cell.

Images